Polymorphisms at APOC3, a gene controlling hepatic triglyceride content, have also been linked to NAFLD, but was later contradicted by a meta-analysis on APOC3 polymorphisms and NAFLD risk [13, 14]. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.